Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):385-94. doi: 10.1016/j.ijrobp.2013.10.043.

Abstract

Purpose: To examine the effects of combined blockade of DNA-dependent protein kinase (DNA-PK) and poly(adenosine diphosphate-ribose) polymerase-1 (PARP-1) on accelerated senescence in irradiated H460 and A549 non-small cell lung cancer cells.

Methods and materials: The effects of KU5788 and AG014699 (inhibitors of DNA-PK and PARP-1, respectively) on clonogenic survival, DNA double-strand breaks (DSBs), apoptosis, mitotic catastrophe, and accelerated senescence in irradiated cells were examined in vitro. For in vivo experiments, H460 xenografts established in athymic nude mice were treated with BEZ235 (a DNA-PK, ATM, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor) and AG014699 to determine effects on proliferation, DNA DSBs, and accelerated senescence after radiation.

Results: Compared with either inhibitor alone, combination treatment with KU57788 and AG014699 reduced postradiation clonogenic survival and significantly increased persistence of Gamma-H2AX (γH2AX) foci in irradiated H460 and A549 cells. Notably, these effects coincided with the induction of accelerated senescence in irradiated cells as reflected by positive β-galactosidase staining, G2-M cell-cycle arrest, enlarged and flattened cellular morphology, increased p21 expression, and senescence-associated cytokine secretion. In irradiated H460 xenografts, concurrent therapy with BEZ235 and AG014699 resulted in sustained Gamma-H2AX (γH2AX) staining and prominent β-galactosidase activity.

Conclusion: Combined DNA-PK and PARP-1 blockade increased tumor cell radiosensitivity and enhanced the prosenescent properties of ionizing radiation in vitro and in vivo. These data provide a rationale for further preclinical and clinical testing of this therapeutic combination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cellular Senescence*
  • Chromones / pharmacology*
  • DNA Breaks, Double-Stranded / drug effects
  • DNA Repair / drug effects
  • DNA-Activated Protein Kinase / antagonists & inhibitors*
  • G2 Phase / drug effects
  • Histones / analysis
  • Imidazoles / pharmacology
  • Indoles / pharmacology*
  • Ki-67 Antigen / analysis
  • Mice
  • Mice, Nude
  • Morpholines / pharmacology*
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Protein Kinase Inhibitors / pharmacology*
  • Quinolines / pharmacology
  • Radiation Tolerance / drug effects*
  • Radiation Tolerance / physiology
  • Tumor Suppressor Protein p53 / analysis
  • beta-Galactosidase / analysis

Substances

  • 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
  • Chromones
  • Histones
  • Imidazoles
  • Indoles
  • Ki-67 Antigen
  • Morpholines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Protein Kinase Inhibitors
  • Quinolines
  • Tumor Suppressor Protein p53
  • gamma-H2AX protein, mouse
  • rucaparib
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1
  • DNA-Activated Protein Kinase
  • beta-Galactosidase
  • dactolisib